Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
OwnerLalage M. Wakefield, Yu-an Yanginventors
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for the suppression of metastasis by a soluble TGF-β antagonist (SR2F). This antagonist is composed of the soluble extracellular domain of the type II TGF-β receptor fused to the Fc domain of human IgG. In particular, the present invention is directed to the use of SR2F to prevent metastasis without affecting the normal physiological role of TGF-β. Thus, the SR2F of the present invention discriminates between “physiological” TGF-β and “pathological” TGF-β in such a manner that only the “pathological” TGF-β is affected by the administration of SR2F.
Claims56
A method for suppressing metastasis, comprising the step of administering a soluble transforming growth factor beta antagonist to a subject having at least one tumor, under conditions such that the normal functions of transforming growth factor beta are not detrimentally affected by said soluble transforming growth factor beta antagonist.
A transgenic non-human animal comprising a soluble transforming growth factor beta antagonist.
A composition comprising a container with a soluble transforming growth factor beta antagonist and instructions for use for treating cancer in a subject.
A method of treating a subject having cancer comprising the steps of:
- a) administering a soluble transforming growth factor beta antagonist
- b) and administering a chemotherapeutic agent.
A method for treating a subject having cancer, comprising the step of administering a soluble transforming growth factor beta antagonist to a subject having at least one tumor, under conditions such that the normal functions of transforming growth factor beta are not detrimentally affected by said soluble transforming growth factor beta antagonist.
A method of treating a subject having cancer comprising the steps of:
- a) administering a soluble transforming growth factor beta antagonist
- b) and administering an immunotherapeutic agent.
Dependencies are inferred from the claim text.